Cellectis (CLLS) EBIT Growth (3y) (2018 - 2026)
Powered by 
Analysis
Cellectis (CLLS) EBIT Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 89.72% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 24.14% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 44.54% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 44.34% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -18.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 81.27% |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | 0.14% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.14% |
| Mar 31, 2026 | 3.30% |
| Dec 31, 2025 | -45.27% |
| Sep 30, 2025 | 31.89% |
| Jun 30, 2025 | 29.46% |
| Mar 31, 2025 | 21.43% |
| Dec 31, 2024 | 35.60% |
| Sep 30, 2024 | 36.65% |
| Jun 30, 2024 | 22.85% |
| Mar 31, 2024 | -1.63% |
| Dec 31, 2023 | -45.29% |
| Sep 30, 2023 | 11.03% |
| Jun 30, 2023 | 10.58% |
| Mar 31, 2023 | -57.83% |
| Dec 31, 2022 | 47.22% |
| Sep 30, 2022 | -0.87% |
| Jun 30, 2022 | 8.04% |
| Mar 31, 2022 | -8.13% |
| Dec 31, 2021 | 5.68% |
| Sep 30, 2021 | -13.60% |